CD302 Antibody

What is CD302 and what is its expression pattern across different tissues?

CD302, also known as CLEC13A, DCL-1, or KIAA0022, is a type I transmembrane C-type lectin receptor (CLR) protein. It represents the simplest CLR described, consisting of 232 amino acids containing a single C-type lectin-like domain . CD302 shows a specific expression pattern in both immune and non-immune tissues:

• Immune cells: Predominantly expressed on myeloid-derived populations including monocytes, macrophages, dendritic cells, and granulocytes

• Liver cells: Abundant expression in human hepatocytes

• Tissue distribution: Primarily expressed in mouse liver, lungs, lymph nodes, and spleen

CD302 expression can be detected via flow cytometry using specific monoclonal antibodies such as clone 771910, which shows distinct staining of CD302 on human peripheral blood monocytes .

What are the structural components of CD302 and how do they contribute to its function?

Human CD302 consists of multiple functional domains, each playing specific roles in its biological activities:

What methodologies can researchers use to detect and quantify CD302 expression?

Several validated methodologies are available for detecting and quantifying CD302 expression:

Flow Cytometry:

• PE-conjugated anti-CD302 antibodies (such as clone 771910) can detect surface expression on peripheral blood monocytes

• Recommended dilutions often need optimization for specific cell types

• Dual staining with CD14 can help identify CD302-expressing monocyte populations

Western Blotting:

• Antibodies like clone 66640-1-Ig can detect CD302 in various human and mouse cell lines

• CD302 typically appears as a 30-32 kDa band, which is higher than the calculated molecular weight (26 kDa) due to glycosylation

• Recommended working dilutions range from 1:1000 to 1:4000

RT-qPCR:

• Can detect transcript variants and quantify expression levels

• Useful for measuring the impact of experimental manipulations on CD302 expression

• Can reveal differential expression between resident and migratory dendritic cell populations

Immunoprecipitation:

• Useful for studying protein-protein interactions, such as the CD302-Cr1l interaction

• Can be combined with mass spectrometry to identify binding partners

How does CD302 contribute to antiviral immunity, particularly against hepatotropic viruses?

CD302 has been identified as a restriction factor that limits hepatitis C virus (HCV) infection through multiple mechanisms:

• Entry inhibition: CD302 preferentially targets the viral entry step of HCV

• Broad spectrum activity: CD302 restricts infection by diverse HCV chimeras representing seven different genotypes

• Hepatitis E virus restriction: CD302 also limits infection by hepatitis E virus (HEV), suggesting broader activity against hepatotropic viruses

• Specificity: CD302 does not affect infection rates of respiratory viruses such as respiratory syncytial virus (RSV) and the alpha coronavirus HCoV-229E

Experimental approaches to study CD302's antiviral function include:

• Overexpression studies using lentiviral vectors carrying CD302 cDNA

• siRNA-mediated knockdown of endogenous CD302 in hepatoma cells and primary hepatocytes

• Time-course analyses measuring viral entry, replication, and release

• Transcriptional profiling to identify dysregulated genes upon CD302 modulation

What role does CD302 play in dendritic cell migration and how can researchers investigate this function?

CD302 exhibits specialized functions in dendritic cell (DC) migration:

• Analysis of lymph node DC subsets reveals 2.5-fold higher CD302 mRNA expression in migratory compared to resident DC populations

• CD302 knockout mice show a modest deficiency in migratory DC numbers in lymph nodes

• CD302 knockout migratory DCs exhibit reduced in vivo migratory capacity to lymph nodes after FITC skin-painting

• CD302 co-localizes with F-actin structures at the near basal surface, including filopodia, lamellipodia, and podosomes

Methodological approaches to study CD302's role in migration include:

• In vivo migration assays: FITC skin-painting followed by tracking of DC migration to draining lymph nodes

• In vitro chemotaxis assays: Measuring migration towards lymphoid-homing chemokines like CCL19/CCL21

• Confocal microscopy: Visualization of CD302 co-localization with cytoskeletal structures

• Knockout mouse models: Comparison of DC migration in wild-type versus CD302-deficient mice

What are the species differences in CD302 function between humans and mice, and what methodologies reveal these differences?

Significant functional differences exist between human and mouse CD302:

Research methodologies to investigate these differences include:

• Cross-species complementation studies

• Comparative transcriptomics of cells expressing human versus mouse CD302

• Domain swapping between human and mouse orthologs

• Humanized mouse models with human CD302 expression

These species differences may contribute to differential susceptibility to hepatotropic viruses and highlight the unique evolutionary trajectories of immune genes in different mammalian lineages .

How does CD302 function as a potential therapeutic target for acute myeloid leukemia (AML)?

CD302 presents several attributes that make it a promising therapeutic target for AML:

• Expression profile: In a cohort of 33 AML patients with varied morphological and karyotypic classifications, 88% expressed CD302 on blast surfaces and 80% on CD34+CD38- cells (enriched with leukemic stem cells)

• Antibody-dependent cell cytotoxicity (ADCC): Monoclonal antibodies targeting human CD302 effectively mediate ADCC

• Internalization capacity: Anti-CD302 antibodies are internalized, making them suitable for toxin conjugation in antibody-drug conjugate (ADC) development

• In vivo efficacy: Targeting CD302 with antibodies limited engraftment of the leukemic cell line HL-60 in NOD/SCID mice

Experimental approaches for investigating CD302 as an AML target include:

• Comprehensive expression profiling across diverse AML subtypes

• Development and screening of anti-CD302 antibodies and ADCs

• In vitro cytotoxicity assays with patient-derived AML samples

• Patient-derived xenograft models to assess in vivo therapeutic efficacy

• Careful evaluation of potential off-target effects on normal CD302-expressing cells

While CD302 is expressed in hepatic cell lines like HepG2, the protein was not detected on their surface, and these cells could not be killed using CD302 antibody-drug conjugates, suggesting potential therapeutic selectivity .

What is the impact of single nucleotide polymorphisms (SNPs) and transcript variants on CD302 function?

Human CD302 exhibits genetic diversity through both SNPs and alternative transcript variants:

Transcript Variants:

• Transcript variant 1 (tv1): Encodes the full-length 232 amino acid protein

• Transcript variant 2 (tv2): Contains in-frame deletion of residues 99-156 within the CTLD

• Transcript variant 3 (tv3): Contains in-frame deletion of residues 23-59

• Transcript variant 4: Does not encode a protein

Single Nucleotide Polymorphisms:
Naturally occurring coding SNPs mapping to different domains of CD302 have been tested and do not influence its capacity to restrict HCV . This suggests a high degree of functional conservation among allelic variants.

Methodological approaches for studying these variants include:

• Cloning individual variants into expression vectors

• Generating stable cell lines expressing specific variants

• Comparative functional assays (viral restriction, migration, etc.)

• Structure-function analyses correlating variant sequence with activity

• Population genetics to assess frequency of variants across different ethnic groups

Understanding the functional impact of these genetic variants may provide insights into individual susceptibility to infections or other CD302-associated conditions.

How does CD302 modulate the hepatocyte transcriptome and what are the methodological challenges in studying this effect?

CD302 exerts significant effects on the hepatocyte transcriptome:

• Knockout effects: RNA-seq profiling of primary hepatocytes from CD302 knockout mice revealed 289 differentially expressed genes (DEGs)

• Pathway impact: Gene Ontology analyses showed dysregulation of genes associated with cellular defense, inflammatory response, and metabolic processing

• Specific targets: Ablation of CD302 expression downregulates genes involved in virus defense (e.g., Apobec1, Isg20, Oasl1) and dysregulates lipid metabolism genes (e.g., Fabp4, Fabp5, Plin5)

• IFN connection: 159 of 289 DEGs were classified as interferon-regulated genes (IRGs)

Methodological challenges in studying CD302's transcriptional effects include:

• Primary cell limitations: Primary hepatocytes rapidly dedifferentiate in culture, complicating extended studies

• Gene manipulation efficiency: Achieving complete knockdown or overexpression in primary hepatocytes is technically challenging

• Constitutive expression: CD302's high basal expression makes complete silencing difficult

• Species differences: Transcriptional networks differ between human and mouse hepatocytes

• Separating direct vs. indirect effects: Distinguishing direct CD302-mediated transcriptional changes from secondary effects

Advanced approaches to address these challenges include using CRISPR-Cas9 for complete gene deletion, developing more sophisticated in vitro culture systems that maintain hepatocyte phenotype, employing inducible expression systems, and validating findings through multiple complementary techniques.

What cytoplasmic domain motifs of CD302 are critical for its functions and how can they be experimentally investigated?

The cytoplasmic domain of CD302 contains several functional motifs that influence its biological activities:

In murine CD302, mutation or deletion of any of these critical residues completely abolished the HCV restriction phenotype . Cell surface expression of cytoplasmic domain mutants was reduced compared to wild-type CD302, although still detectable .

Experimental approaches to investigate these motifs include:

• Site-directed mutagenesis: Targeting specific residues to create alanine substitutions or other modifications

• Trafficking studies: Using fluorescently tagged constructs to track subcellular localization

• Phosphorylation analysis: Mass spectrometry or phospho-specific antibodies to detect post-translational modifications

• Palmitoylation assays: Using click chemistry or metabolic labeling to detect lipid modifications

• Protein-protein interaction studies: Identifying binding partners that interact with specific cytoplasmic motifs

• Functional rescue experiments: Testing whether wild-type cytoplasmic domain can restore function to CTLD-only constructs

Understanding these cytoplasmic domain interactions may reveal how CD302 connects to downstream signaling pathways and cellular machinery.

What are the critical considerations when selecting anti-CD302 antibodies for different experimental applications?

Researchers should consider several factors when selecting anti-CD302 antibodies:

Application-specific requirements:

• Flow cytometry: Choose antibodies validated for surface staining, preferably directly conjugated (e.g., PE-conjugated clone 771910)

• Western blotting: Select antibodies recognizing denatured epitopes (e.g., clone 66640-1-Ig works at 1:1000-1:4000 dilution)

• Immunoprecipitation: Choose antibodies with high affinity and specificity for native protein

• ELISA: Antibodies like clone 4C10-F11-C10 are optimized for ELISA at specific dilutions (1:160,000)

Epitope location considerations:

• Antibodies targeting the CTLD will not detect ΔCTLD mutants

• Domain-specific antibodies can help distinguish transcript variants

• Consider whether the epitope might be masked by interaction partners

Species reactivity:

• Some antibodies show cross-reactivity between human and mouse CD302 (e.g., clone 66640-1-Ig)

• Others are species-specific and should be selected according to the experimental system

Clone selection:

• Clone 771910 has been validated for detection of CD302 in human monocytes by flow cytometry

• Clone 4C10-F11-C10 was developed from E. coli-derived recombinant human CD302 protein and works well in ELISA

Proper antibody validation, including appropriate positive and negative controls, is essential for accurate interpretation of results.

What are the most effective approaches for modulating CD302 expression in experimental systems?

Several approaches can be employed to modulate CD302 expression experimentally:

Knockdown strategies:

• siRNA transfection: Achieves moderate (50-80%) reduction in CD302 expression

• shRNA lentiviral delivery: Provides more stable, long-term knockdown

• esiRNAs (endoribonuclease-prepared siRNAs): Can reduce CD302 cell surface expression

Knockout methods:

• CRISPR-Cas9 targeting of Exon 1: Completely ablates functional CD302 protein expression

• TALENs or zinc-finger nucleases: Alternative genome editing approaches

Overexpression systems:

• Lentiviral vectors carrying CD302 cDNA: Provide stable, long-term expression

• Inducible expression systems: Allow temporal control of CD302 expression

• Domain deletion constructs (ΔCTLD, ΔCPT): Enable structure-function studies

Mutant generation:

• Site-directed mutagenesis targeting specific residues (C213, Y209, Y223, EEDE motif)

• Domain swapping between human and mouse orthologs

• Transcript variant-specific constructs

The effectiveness of these approaches should be validated by:

• RT-qPCR to confirm transcript modulation

• Western blotting to verify protein level changes

• Flow cytometry to assess cell surface expression

• Functional assays to confirm biological impact

What are the methodological challenges in studying CD302 function in primary hepatocytes and how can they be addressed?

Studying CD302 in primary hepatocytes presents several technical challenges:

Challenge 1: Isolation and maintenance of primary hepatocytes

• Primary hepatocytes rapidly dedifferentiate in conventional culture

• Solution: Use sandwich cultures with extracellular matrix overlay, micropatterned co-cultures, or 3D spheroid models to maintain hepatocyte phenotype

Challenge 2: Genetic manipulation efficiency

• Primary hepatocytes are difficult to transfect efficiently

• Solution: Use optimized hepatocyte-specific transfection reagents, adenoviral or lentiviral vectors with high tropism for hepatocytes, or electroporation protocols

Challenge 3: Interferon responses

• Silencing CD302 in primary human hepatocytes is complicated by robust interferon responses

• Solution: Use JAK/STAT inhibitors like ruxolitinib to blunt interferon responses and create a larger window for experimental measurements

Challenge 4: Constitutive CD302 expression

• High basal expression makes complete knockdown difficult

• Solution: Use CRISPR-Cas9 for complete gene deletion rather than relying on RNA interference

Challenge 5: Species differences

• Significant functional differences between human and mouse CD302

• Solution: Develop humanized mouse models, validate findings across species, and carefully interpret cross-species data

Challenge 6: Variant isoforms

• Multiple transcript variants require careful experimental design

• Solution: Use isoform-specific reagents and consider potential differences in isoform abundance between in vitro and in vivo settings

Advanced approaches such as single-cell RNA-seq, CRISPR screens, and organoid models are increasingly being employed to overcome these methodological challenges.

How might CD302 interact with other C-type lectin receptors in coordinated immune responses?

While CD302 represents the simplest type I transmembrane C-type lectin receptor described , its potential interactions with other CLRs remain largely unexplored. Key research considerations include:

• Co-expression patterns: CD302 is expressed in myeloid cells alongside other CLRs like Dectin-1, DC-SIGN, and Mincle

• Signaling integration: How CD302 signaling might complement or antagonize other CLR pathways

• Heterodimer formation: Potential for CD302 to form heterodimers with other CLRs

• Evolutionary conservation: Whether CD302's interactions with other CLRs differ between species

Research approaches should include:

• Co-immunoprecipitation studies to identify physical interactions

• Phosphoproteomic analyses to map shared signaling pathways

• CRISPR screens to identify functional dependencies

• Single-cell analyses to reveal co-expression patterns in different cell states

Understanding these interactions could reveal how CD302 contributes to the broader CLR network in coordinating immune responses.

How can the antiviral properties of CD302 be leveraged for therapeutic development?

CD302's activity against hepatotropic viruses suggests potential therapeutic applications:

• Broad-spectrum antivirals: Since CD302 restricts both HCV and HEV , it might serve as a template for developing broad-spectrum antivirals against hepatotropic viruses

• Small molecule enhancers: Compounds that enhance CD302 expression or activity could boost intrinsic antiviral immunity

• Peptide therapeutics: Peptides derived from the CTLD domain might mimic CD302's antiviral effects

• Gene therapy approaches: Targeted overexpression of CD302 in liver cells could enhance resistance to viral infection

Methodological approaches include:

• High-throughput screening for compounds that enhance CD302 expression or function

• Structure-based drug design targeting the CTLD

• Ex vivo testing using primary human hepatocytes or liver organoids

• Humanized mouse models for in vivo validation

Key challenges involve tissue-specific delivery, potential immunogenicity, and ensuring specificity to avoid disrupting CD302's physiological functions in immune cells.

What is the significance of CD302's constitutive expression in hepatocytes compared to interferon-inducible antiviral factors?

CD302 represents an interesting example of a constitutively expressed antiviral factor:

• Unlike classical interferon-stimulated genes (ISGs), CD302 expression in hepatocytes is constitutive and not inducible by interferon

• Both human and mouse CD302 expression is not modulated by RIG-I or TLR3 sensing pathways

• CD302 provides a baseline level of antiviral protection that is independent of interferon signaling

• This constitutive expression may contribute to the liver's first line of defense against viral infections

Research questions to explore include:

• What transcription factors control CD302's constitutive expression?

• How does CD302 cooperate with interferon-inducible factors during viral infection?

• Are there conditions that can modulate CD302 expression if not interferon?

• Does constitutive expression of CD302 influence the liver's tolerogenic environment?

Experimental approaches should include chromatin immunoprecipitation to identify transcription factors binding the CD302 promoter, enhancer mapping, and studies comparing CD302's antiviral activity with and without functional interferon signaling.